FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553696906> ?p ?o ?g. }

• W2553696906 abstract "Abstract Abstract 4935 Background: Myelodysplasticsyndromes (MDS) are a heterogeneous group of hematopoietic diseases characterized by peripheral blood cytopenias and increased apoptosis of precursor cells in the marrow. Current therapies are focused on disease control, with no cure other than allogeneic stem cell transplantation. Decitabine is known to act as a hypomethylator while lenalidomide has multiple affects, including actions on the stromal marrow cell interaction. It is hypothesized that the combination of decitabine with lenalidomide may show synergistic results. Thus we performed a phase 1 study to estimate the maximally tolerated dose of lenalidomide in combination with decitabine in patients with high risk MDS. Methods: Adults with primary or secondary MDS, including all subcategories and IPSS risk categories of INTERM-2 or High were eligible, including those who had prior therapy even if they progressed with prior exposure to hypomethylators. Patients also must have had CrCl 3 60ml/min, and liver function test 2 3 × ULN. Following a standard phase 1 3+3 design, patients received decitabine 20mg/m2 over one hour intravenously daily for 5 days, with cycles repeated every 28 days. Lenalidomide was given in cohorts at doses of 5mg, 10mg, or 15mg daily for days 1–21 of the 28 day cycle. Patients were analyzed during the first cycle for dose limiting toxicity and responders that did not have a DLT could continue until progression or toxicity required discontinuation. DLT was defined as any non-heme grade 3 toxicity (CTC v. 4) that was study related lasting 3 7 days or grade 4 of any duration or Neutropenia or thrombocytopenia 3 grade 3 due to study agents >14 days. Results: Patients and disease characteristics are noted in the table below. Twelve evaluable patients were treated, 5 had prior therapy (all included a hypomethylator). The combination seems tolerable, though toxicities included the following: 4 patients had a grade 3 febrile neutropenia (2 in cohorts 1 and 3 each), 2 with grade 2 rash (1 cohorts 1 and 3 each), and 4 with grade 3 anorexia/fatigue (1 cohort 1, 2 cohort 2, 1 cohort 3). With median duration of follow up for survivors of 6 months (2–38months) the median number of cycles of therapy was 4 (1–16) with 3 continuing on therapy at this time. Responses were noted at all dose levels, including those with prior hypomethylator exposure (see table 1): 3 (25%) complete responders, 1 partial responder (8%), and 3 (25%) with stable disease. The Median duration of response was 5 months (1–21) with 3 continuing in response. Conclusion: In patients with high risk MDS, the combination of decitabine and lenalidomide is tolerable and provides encouraging response rates in this population. The MTD was determined as decitabine 20mg/m2 daily for 5 days with lenalidomide 10mg daily for days 1–21 of a 28 day cycle. Larger studies of this combination are warranted. *MTD Disclosures: Rizzieri: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Beaven:Celgene: Research Funding." @default.
• W2553696906 created "2016-11-30" @default.
• W2553696906 creator A5001517281 @default.
• W2553696906 creator A5017626038 @default.
• W2553696906 creator A5034905618 @default.
• W2553696906 creator A5056482233 @default.
• W2553696906 creator A5056698355 @default.
• W2553696906 creator A5061865992 @default.
• W2553696906 creator A5075225618 @default.
• W2553696906 creator A5078351605 @default.
• W2553696906 creator A5086211539 @default.
• W2553696906 creator A5090270559 @default.
• W2553696906 date "2012-11-16" @default.
• W2553696906 modified "2023-09-29" @default.
• W2553696906 title "Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS" @default.
• W2553696906 doi "https://doi.org/10.1182/blood.v120.21.4935.4935" @default.
• W2553696906 hasPublicationYear "2012" @default.
• W2553696906 type Work @default.
• W2553696906 sameAs 2553696906 @default.
• W2553696906 citedByCount "0" @default.
• W2553696906 crossrefType "journal-article" @default.
• W2553696906 hasAuthorship W2553696906A5001517281 @default.
• W2553696906 hasAuthorship W2553696906A5017626038 @default.
• W2553696906 hasAuthorship W2553696906A5034905618 @default.
• W2553696906 hasAuthorship W2553696906A5056482233 @default.
• W2553696906 hasAuthorship W2553696906A5056698355 @default.
• W2553696906 hasAuthorship W2553696906A5061865992 @default.
• W2553696906 hasAuthorship W2553696906A5075225618 @default.
• W2553696906 hasAuthorship W2553696906A5078351605 @default.
• W2553696906 hasAuthorship W2553696906A5086211539 @default.
• W2553696906 hasAuthorship W2553696906A5090270559 @default.
• W2553696906 hasConcept C104317684 @default.
• W2553696906 hasConcept C126322002 @default.
• W2553696906 hasConcept C143998085 @default.
• W2553696906 hasConcept C150194340 @default.
• W2553696906 hasConcept C185592680 @default.
• W2553696906 hasConcept C190727270 @default.
• W2553696906 hasConcept C2776063141 @default.
• W2553696906 hasConcept C2776364478 @default.
• W2553696906 hasConcept C2778715236 @default.
• W2553696906 hasConcept C2780007613 @default.
• W2553696906 hasConcept C2780235182 @default.
• W2553696906 hasConcept C2780817109 @default.
• W2553696906 hasConcept C29730261 @default.
• W2553696906 hasConcept C31760486 @default.
• W2553696906 hasConcept C55493867 @default.
• W2553696906 hasConcept C71924100 @default.
• W2553696906 hasConcept C90924648 @default.
• W2553696906 hasConcept C98274493 @default.
• W2553696906 hasConceptScore W2553696906C104317684 @default.
• W2553696906 hasConceptScore W2553696906C126322002 @default.
• W2553696906 hasConceptScore W2553696906C143998085 @default.
• W2553696906 hasConceptScore W2553696906C150194340 @default.
• W2553696906 hasConceptScore W2553696906C185592680 @default.
• W2553696906 hasConceptScore W2553696906C190727270 @default.
• W2553696906 hasConceptScore W2553696906C2776063141 @default.
• W2553696906 hasConceptScore W2553696906C2776364478 @default.
• W2553696906 hasConceptScore W2553696906C2778715236 @default.
• W2553696906 hasConceptScore W2553696906C2780007613 @default.
• W2553696906 hasConceptScore W2553696906C2780235182 @default.
• W2553696906 hasConceptScore W2553696906C2780817109 @default.
• W2553696906 hasConceptScore W2553696906C29730261 @default.
• W2553696906 hasConceptScore W2553696906C31760486 @default.
• W2553696906 hasConceptScore W2553696906C55493867 @default.
• W2553696906 hasConceptScore W2553696906C71924100 @default.
• W2553696906 hasConceptScore W2553696906C90924648 @default.
• W2553696906 hasConceptScore W2553696906C98274493 @default.
• W2553696906 hasLocation W25536969061 @default.
• W2553696906 hasOpenAccess W2553696906 @default.
• W2553696906 hasPrimaryLocation W25536969061 @default.
• W2553696906 hasRelatedWork W2463213105 @default.
• W2553696906 hasRelatedWork W2473200387 @default.
• W2553696906 hasRelatedWork W2497895663 @default.
• W2553696906 hasRelatedWork W2530606198 @default.
• W2553696906 hasRelatedWork W2537548903 @default.
• W2553696906 hasRelatedWork W2550855140 @default.
• W2553696906 hasRelatedWork W2554302125 @default.
• W2553696906 hasRelatedWork W2556795736 @default.
• W2553696906 hasRelatedWork W2567429037 @default.
• W2553696906 hasRelatedWork W2568433166 @default.
• W2553696906 hasRelatedWork W2576173852 @default.
• W2553696906 hasRelatedWork W2582987634 @default.
• W2553696906 hasRelatedWork W2594206356 @default.
• W2553696906 hasRelatedWork W2597034369 @default.
• W2553696906 hasRelatedWork W2907930551 @default.
• W2553696906 hasRelatedWork W2979613703 @default.
• W2553696906 hasRelatedWork W2980073076 @default.
• W2553696906 hasRelatedWork W2980140263 @default.
• W2553696906 hasRelatedWork W2980857653 @default.
• W2553696906 hasRelatedWork W386940765 @default.
• W2553696906 isParatext "false" @default.
• W2553696906 isRetracted "false" @default.
• W2553696906 magId "2553696906" @default.
• W2553696906 workType "article" @default.